Pfizer recalls Dopamine HCl Inj.
- Published
- 23 Sept 2026
- Units affected
- N/A
- Agency
- FDA
- Country
- United States
The hazard
Lack of Assurance of Sterility
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
- Brand / company
- Pfizer
- Codes / lots
- Lot # NL5230, Exp Date:10/2027
- Distribution
- US Nationwide.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 23 Sept 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.